Lung Cancer Trials


















GO29436: A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Paclitaxel With or Without Bevacizumab in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower 150]

GO29437: A Phase III Study of MPDL3280A (Anti-PD-L1) in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 131]

ALCHEMIST A151216: Genetic testing in screening patients with stage IB-IIIA Non small cell lung cancer that has been removed by surgery

E4512: Crizotinib in treating patients with Stage IB-IIIA Non small cell lung cancer that has been removed by surgery and has ALK Fusion mutation

A081105: Tarceva in treating patients with Stage IB-IIIA non small cell lung cancer that has been completely removed by surgery.

S1400 Bio-Marker driven master protocol for 2nd line therapy of squamous cell lung cancer

Click here for more information on the newest lung cancer trial.